What’s the current market cap for Arvinas stock?

Arvinas (ARVN) has a market cap of $570M as of May 29, 2026.

What is the P/E ratio for Arvinas stock?

The price to earnings (P/E) ratio for Arvinas (ARVN) stock is 0 as of May 29, 2026.

Does Arvinas stock pay dividends?

No, Arvinas (ARVN) stock does not pay dividends to its shareholders as of May 29, 2026.

When is the next Arvinas dividend payment date?

Arvinas (ARVN) stock does not pay dividends to its shareholders.

What is the beta indicator for Arvinas?

Arvinas (ARVN) has a beta rating of 1.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Arvinas stock | $ARVN Share Price

13:30

15:10

16:45

18:25

20:00

About Arvinas

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Ticker

$ARVN

Sector

Health

Primary listing

NASDAQ

Employees

246

Headquarters

New Haven, United States

Website

www.arvinas.com

Arvinas Metrics

BasicAdvanced

$570m

-$3.22

1.80

What the Analysts think about Arvinas

Analyst ratings (Buy, Hold, Sell) for Arvinas stock.

Bulls say / Bears say

The U.S. FDA approved Pfizer and Arvinas’ breast cancer drug vepdegestrant (VEPPANU), granting the first-ever PROTAC therapy approval and confirming the value of the company’s protein degradation platform (Reuters)

Arvinas confirmed $685 million in available cash with funding expected into the second half of 2028, supporting its ability to move multiple clinical and regulatory projects forward (Reuters)

Positive Phase 1 results for ARV-102 showed over 50% reduction of LRRK2 in cerebrospinal fluid in Parkinson’s patients after 28 days, highlighting the PROTAC platform’s promise in neurodegenerative disease treatment (Reuters)

Arvinas’ Q1 2026 revenue dropped sharply to $15.6 million from $188.8 million a year ago, showing the company’s strong dependence on one-time collaboration payments rather than steady product sales (Investing.com)

Arvinas and Pfizer will license out vepdegestrant to a third party, giving up control and reducing Arvinas’ future share of revenue from its first approved PROTAC therapy (Reuters)

The companies removed two planned Phase 3 combination trials of vepdegestrant from their joint development plan, shrinking the scope and delaying possible progress of its main oncology program (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

Arvinas Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Arvinas Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARVN

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Arvinas confirmed $685 million in available cash with funding expected into the second half of 2028, supporting its ability to move multiple clinical and regulatory projects forward (Reuters)

Arvinas and Pfizer will license out vepdegestrant to a third party, giving up control and reducing Arvinas’ future share of revenue from its first approved PROTAC therapy (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.